I have read several announcements. Heard the odd interview with management.
MSB is a big opportunity cost for me right now. It's balance sheet is a shocker and it has no FDA approvals.
Imho it's balance sheet will be guiding decision making again.
Not a good position to be in with net negative assets (excluding IP).
USD573M in retained losses and a less than great 2020!. 2021 a year that cannot get worse, page-66
-
- There are more pages in this discussion • 246 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.18 |
Change
0.013(1.07%) |
Mkt cap ! $1.358B | |||
| Open | High | Low | Value | Volume |
| $1.15 | $1.20 | $1.15 | $1.344M | 1.148M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 2929 | $1.18 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.18 | 61849 | 9 |
View Market Depth
| Last trade - 11.11am 16/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |